- Home
- JANX vs DNTH Comparison
JANX vs DNTH Comparison
Compare JANX & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JANX
- DNTH
- Stock Information
- Founded
- JANX 2017
- DNTH 2015
- Country
- JANX United States
- DNTH United States
- Employees
- JANX N/A
- DNTH N/A
- Industry
- JANX Biotechnology: Pharmaceutical Preparations
- DNTH Biotechnology: Pharmaceutical Preparations
- Sector
- JANX Health Care
- DNTH Health Care
- Exchange
- JANX Nasdaq
- DNTH Nasdaq
- Market Cap
- JANX 1.4B
- DNTH 1.5B
- IPO Year
- JANX 2021
- DNTH N/A
- Fundamental
- Price
- JANX $27.01
- DNTH $34.94
- Analyst Decision
- JANX Strong Buy
- DNTH Strong Buy
- Analyst Count
- JANX 11
- DNTH 11
- Target Price
- JANX $76.55
- DNTH $65.22
- AVG Volume (30 Days)
- JANX 927.5K
- DNTH 608.1K
- Earning Date
- JANX 11-05-2025
- DNTH 11-06-2025
- Dividend Yield
- JANX N/A
- DNTH N/A
- EPS Growth
- JANX N/A
- DNTH N/A
- EPS
- JANX N/A
- DNTH N/A
- Revenue
- JANX $439,000.00
- DNTH $4,854,000.00
- Revenue This Year
- JANX N/A
- DNTH N/A
- Revenue Next Year
- JANX $91.66
- DNTH N/A
- P/E Ratio
- JANX N/A
- DNTH N/A
- Revenue Growth
- JANX N/A
- DNTH 17.87
- 52 Week Low
- JANX $21.73
- DNTH $13.37
- 52 Week High
- JANX $71.71
- DNTH $40.16
- Technical
- Relative Strength Index (RSI)
- JANX 59.54
- DNTH 51.00
- Support Level
- JANX $25.62
- DNTH $34.63
- Resistance Level
- JANX $27.70
- DNTH $37.50
- Average True Range (ATR)
- JANX 1.56
- DNTH 2.03
- MACD
- JANX 0.30
- DNTH -0.43
- Stochastic Oscillator
- JANX 69.68
- DNTH 26.49
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.